ArticleTheranostics2022
Extracellular ATP is increased by release of ATP-loaded microparticles triggered by nutrient deprivation.
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Effects on mouse melanoma and immune cells of P2X7 receptor positive allosterism by clemastine.Purinergic signalling · 2026Article
- The P2X7 receptor: insights from the murine monoclonal antibody clone L4.Purinergic signalling · 2026Review
- P2RY6Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Methodological guidelines for P2X receptor assays and data interpretation.Cell death & disease · 2026Review
- Caloric Restriction Mimetic Hydroxycitrate Mitigates Acute Nephrotoxicity via Autophagy Activation and Oxidative Stress Reduction.Biomolecules · 2026Article
- Latest advances on the role of P2X Receptors in colorectal inflammation and cancer.Purinergic signalling · 2026Review
- The purinergic signaling interfaces in breast cancer angiogenesis.Purinergic signalling · 2026Review
- P2X7 a new therapeutic target to block vesicle-dependent metastasis in colon carcinoma: Role of the A2A/CD39/CD73 axis.Cell death & disease · 2025Article
- Senolytic Treatment Attenuates Global Ischemic Brain Injury and Enhances Cognitive Recovery by Targeting Mitochondria.Cellular and molecular neurobiology · 2025Article
- Leveraging adenosine triphosphate for cancer theranostics.Theranostics · 2025Review
- Clodronate Reduces ATP-Containing Microvesicle Releasing Induced by Nociceptive Stimuli in Human Keratinocytes.International journal of molecular sciences · 2024Article
- Current advances in cancer energy metabolism under dietary restriction: a mini review.Medical oncology (Northwood, London, England) · 2024Review
- The ATP-exporting channel Pannexin 1 promotes CD8iScience · 2024Article
- The P2X7 Receptor is a Master Regulator of Microparticle and Mitochondria Exchange in Mouse Microglia.Function (Oxford, England) · 2024Article
- The ATP-exporting channel Pannexin-1 promotes CD8bioRxiv : the preprint server for biology · 2024Article
- Fetal bovine serum contains biologically available ATP.Purinergic signalling · 2024Article
- Purinergic enzymes on extracellular vesicles: immune modulation on the go.Frontiers in immunology · 2024Review
- Mitochondrial transplantation reduces lower limb ischemia-reperfusion injury by increasing skeletal muscle energy and adipocyte browning.Molecular therapy. Methods & clinical development · 2023Article
- Purine and purinergic receptors in health and disease.MedComm · 2023Review
- The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.